POMBILITI

This brand name is authorized in Austria, Spain, France, Ireland, Lithuania, Poland, United Kingdom

Active ingredients

The drug POMBILITI contains one active pharmaceutical ingredient (API):

1 Cipaglucosidase alfa UNII 4SED7F4BSG - CIPAGLUCOSIDASE ALFA

Sipaglucosidase alfa is intended to replace the endogenous enzyme acid-alpha-glucosidase (GAA) that breaks down glycogen to glucose in the lysosome and is absent or impaired in Pompe disease. Sipaglucosidase alfa exerts enzymatic activity in the breakdown of glycogen and the reduction of intramuscular glycogen, as well as the amelioration of tissue damage. Read about Cipaglucosidase alfa

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
POMBILITI Powder for concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AB23		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1221714001
Country: FR	Base de données publique des médicaments	Identifier(s): 64427538
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1096835, 1096836, 1096837